Center news
RADx Tech COVID-19 Funding Opportunity High-Performance COVID-19 Rapid Tests
The RADx Coordination Center at CIMIT, on behalf of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health (NIH), is soliciting proposals to further advance next-generation (next-gen) over-the-counter (OTC) and point-of-care (POC) testing technologies for COVID-19 under its Rapid Acceleration of Diagnostics (RADx) fast-track program.
Under this RADx Tech Performance solicitation, NIBIB is seeking to accelerate the development of next Next-Gen COVID-19 diagnostic technologies with a focus on performance innovations: Innovations that provide significantly improved clinical and technical performance compared to current, best-in-class OTC/POC technologies. These platforms must also integrate universal design features in order to ensure the broadest possible ease of use and accessibility for all populations. Test platforms should return results quickly, demonstrate potential for integration with digital health reporting standards, and be capable of achieving regulatory clearance during both pandemic and non-pandemic periods.
The RADx Coordination Center at CIMIT, on behalf of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health (NIH), is soliciting proposals to further advance next-generation (next-gen) over-the-counter (OTC) and point-of-care (POC) testing technologies for COVID-19 under its Rapid Acceleration of Diagnostics (RADx) fast-track program.
Under this RADx Tech Performance solicitation, NIBIB is seeking to accelerate the development of next Next-Gen COVID-19 diagnostic technologies with a focus on performance innovations: Innovations that provide significantly improved clinical and technical performance compared to current, best-in-class OTC/POC technologies. These platforms must also integrate universal design features in order to ensure the broadest possible ease of use and accessibility for all populations. Test platforms should return results quickly, demonstrate potential for integration with digital health reporting standards, and be capable of achieving regulatory clearance during both pandemic and non-pandemic periods.